Nextar Chempharma Solutions

About

Company Intelligence Q&A

Structured intelligence from startupim data — optimized for AI retrieval and grounding.

What is Nextar Chempharma Solutions' primary focus?

Nextar Chempharma Solutions specializes in the development and manufacturing of drugs and medical devices, with a focus on contract drug development and manufacturing.

What is Nextar Chempharma Solutions' proprietary technology?

Nextar Chempharma Solutions has a proprietary Brain Targeted Liposomes (BTLS) platform designed for targeted delivery of drugs across the blood-brain barrier and into the brain.

When was Nextar Chempharma Solutions founded?

Nextar Chempharma Solutions was founded in July 2007.

What was a significant financial event for Nextar Chempharma Solutions in 2022?

In July 2022, Nextar Chempharma Solutions received a grant of $370,000 from the IIA.

What was the outcome of a mouse trial for glioblastoma treatment using Nextar's BTLS platform?

In September 2023, Nextar announced positive final results from a mouse trial demonstrating the efficacy of glioblastoma brain cancer treatment based on its BTLS platform.

What acquisition event is noted for Nextar Chempharma Solutions?

Nextar Chempharma Solutions was acquired in March 2025.

What was the nature of the agreement between Nextage and Nextar in September 2023?

In September 2023, Nextage signed an agreement to merge with Nextar Chempharma Solutions, valuing Nextar at no less than 78 million NIS.

What was Nextar Chempharma Solutions' involvement with medical cannabis in 2017?

In November 2017, Nextar Chempharma Solutions was setting up a medical cannabis incubator.

Sectors & technology

Highlights

Tags